Please ensure Javascript is enabled for purposes of website accessibility

AbbVie Strikes Deal With the FTC to Move Its Allergan Acquisition Forward

By Prosper Junior Bakiny - Mar 18, 2020 at 11:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The blockbuster pharmaceutical deal has had its share of detractors.

In June, AbbVie (ABBV 1.93%) made a bid to purchase Allergan (AGN) in a cash and stock transaction valued at $63 billion. AbbVie likely decided to pursue the massive acquisition in part to decrease its reliance on its best-selling drug Humira, sales of which have been declining in Europe due to competition from biosimilars. However, the deal has faced some resistance. In a letter sent to the U.S. Federal Trade Commission (FTC) in September, a coalition of consumer groups and unions expressed their concerns that AbbVie's acquisition of Allergan "will likely harm consumers." The coalition asked the FTC to investigate further, and potentially block the acquisition. 

Doctor giving a thumbs up

Image Source: Getty Images.

Selling assets to reduce the anticompetitive risks

AbbVie and Allergan have agreed to divest some of their assets to move the acquisition forward, and the pharma giants recently reached an agreement with the FTC on the deal. Allergan agreed to sell Brazikumab -- a drug in its pipeline that is being developed as a treatment for Crohn's disease and ulcerative colitis -- to AstraZeneca (AZN 3.80%). Allergan will also be selling Zenpep -- an enzyme-replacement therapy used by patients with conditions such as cystic fibrosis -- to Nestle (NSRGY 3.09%). The acquisition of Allergan was initially supposed to close during the first quarter of 2020. However, AbbVie now says it expects the deal to close in May. Still, the good news is that AbbVie should not encounter any more obstacles now that is has reached a deal with the FTC. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Allergan plc Stock Quote
Allergan plc
AGN
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$152.34 (1.93%) $2.89
Nestle S.A. Stock Quote
Nestle S.A.
NSRGY
$116.87 (3.09%) $3.50
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.90 (3.80%) $2.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.